BMY63.43+1.11 (+1.78%) session● PRIOR SESSION CLOSE

BMYcited research thesis

BMY — what changed and why it matters

House verdict · BMY · multi-desk debate + self-falsification

No sealed verdict on BMY yet

No debate has been run on BMY; debates rotate through a watchlist. The conviction call below is the signal engine’s output — one input to a debate, not a multi-desk verdict. Sealed debates on other names, each with its falsification check, are available.

Open the Glass Box →

Individual · $49 a monthThe conviction call on BMY — outside the public coverage list

Covered names include the conviction call in the sealed record at no charge. BMY is outside public coverage; running the signal engine on it requires a seat. The panels above do not depend on it.

Start checkout →

PRE-EARNINGS THESIS — written 2026-09-25, before the 2026-10-29 earnings report; nothing below reflects that report. A refresh is queued for the session a covered name reports or moves sharply. A same-session re-derive is queued when a covered name prints or moves sharply; until the refreshed read lands, nothing below reflects that report.

0 of 9 figures below re-derived from a sourcewritten 2026-09-25

This thesis is 49 days old. Statements below are as of 2026-09-25.

BMY — what moved and why today

Context (knowledge graph)

AtlasVector tracks 20 related entities for BMY in its knowledge graph. ^[c1]

What changed

Acadia Pharmaceuticals Fell 19% Today. Here’s Where the Stock Could Go in 2026
Bristol Myers Squibb (BMY) Adds Restricted Pharmacy Path For New Myeloma Drug
Top Stock Reports for Tesla, sell-side note & Coca-Cola

Valuation spine (rich/cheap)

^[c5]

Key takeaways

Acadia Pharmaceuticals Fell 19% Today. Here’s Where the Stock Could Go in 2026
Bristol Myers Squibb (BMY) Adds Restricted Pharmacy Path For New Myeloma Drug
Top Stock Reports for Tesla, sell-side note & Coca-Cola

Headlines · BMY AS OF 2026-11-14 02:23Z

11-13 17:14ZCan BMY Sustain Growth in Its Cardiovascular Franchise?Zacks Investment Research
11-13 22:42ZAmgen vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy for 2027?The Motley Fool
11-12 14:44ZREPL Stock Up 80% in a Month on Tudriqev Launch & Pipeline ProgressZacks Investment Research
11-09 12:51ZWill Bristol Myers' Growth Brands Offset Eliquis Headwinds?Zacks Investment Research
11-09 12:48ZMRK's 2027 Outlook Challenging, Long-Term Prospects PromisingZacks Investment Research
11-09 10:00ZBioNTech vs. Moderna: The COVID Vaccine Giants Are Entering a New Era. One Stock Could Have the Edge for 2027The Motley Fool

Provenance

verdicts, debates and hash-chained audit seals recorded against BMY

Instruments 1

BMY2026-11-12

Session bars 5

BMY · Thu Nov 12 session barBMY2026-11-12
BMY · Wed Nov 11 session barBMY2026-11-11
BMY · Tue Nov 10 session barBMY2026-11-10
BMY · Mon Nov 09 session barBMY2026-11-09
BMY · Thu Oct 29 session barBMY2026-10-29

Screen metrics 1

BMY · screen metrics · Thu Nov 12BMY2026-11-12

7 recorded entities · 6 links. synthetic = the row is flagged as built on synthetic inputs; no provenance = the store holds no synthetic flag for the row. Unmarked rows are flagged non-synthetic. Chain seals list sequence number, event key and SHA-256 chain hash. Verify seal opens the verdict's proof panel, where the sealed record is re-hashed in the browser and compared against the seal.

Cited sources · 5

[c1]AtlasVector knowledge graphgraph context for BMY

[c2]NewswireAcadia Pharmaceuticals Fell 19% Today. Here’s Where the Stock Could Go in 2026

[c3]NewswireBristol Myers Squibb (BMY) Adds Restricted Pharmacy Path For New Myeloma Drug

[c4]NewswireTop Stock Reports for Tesla, sell-side note & Coca-Cola

[c5]AtlasVector valuation spineconsensus valuation

The full record is in AtlasVector.

Standing monitors, multi-desk debate, audited paper trading and a persistent research record.

Open AtlasVector →